Incidence of Guillain-Barré Syndrome After COVID-19 Vaccination in the Vaccine Safety Datalink

Kayla E. Hanson et al.

Are COVID-19vaccines associated with Guillain-Barré syndrome (GBS)?

In this cohort study of surveillance data from the Vaccine Safety Datalink that included 15.1 million doses of COVID-19 vaccines, the unadjusted incidence rate of confirmed GBS in the 1 to 21 days after receiving the Ad.26.COV2.S (Janssen) vaccine was 32.4 per 100 000 person-years, which was significantly higher than the background rate of GBS. The unadjusted incidence rate of confirmed GBS in the 1 to 21 days after mRNA vaccines was 1.3 per 100 000 person-years, which did not differ from the background rate.

These findings suggest an increased risk of GBS after Ad.26.COV2.S vaccination.

Latest articles

Aseem Malhotra In response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),...
Aseem Malhotra Authorities and sections of the medical profession have supported unethical,...
Bill Sanda For many years, Dr. Meira Fields and her coworkers at...
Christina Szalinski Nearly half of U.S. infant formula contain corn sugars. Mounting...

Your donation helps us
stand up for health freedom!

Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.

Thank you!

The form has been submitted successfully!